| PTC THERAPEUTICS DL-,001 |
| USA |
| Gesundheit |
| US69366J2006 / A1W0MW |
| BH3 (Frankfurt) / PTCT (NASDAQ) |
| FRA:BH3, ETR:BH3, BH3:GR, NASDAQ:PTCT |
| - |
| https://www.ptcbio.com/ |
|
Ptc Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines for patients living with rare disorders, particularly orphan diseases affecting children and adults. The company specialize..
>Volltext.. |
| 4697.82 Mio. EUR |
| 3392.65 Mio. EUR |
| 1496.38 Mio. EUR |
| 774.12 Mio. EUR |
| 590.23 Mio. EUR |
| 7.6 EUR |
| 344.73 Mio. EUR |
| 851.36 Mio. EUR |
| 614.92 Mio. EUR |
| 2.01 |
| 89.07% |
| - |
| - |
| - |
| - |
| PTC THERAPEUTICS, PTC THERAPEUTIC, PTC THERA |
| 01.04.26 |